Multiply Labs Raises $75M for Robotic Biomanufacturing

A therapy can survive discovery, clinical testing, and regulatory review, then meet a factory built for a different kind of medicine. Multiply Labs has raised a $75M Series B to push that final handoff toward robotic production.

Dr. Patrick Soon-Shiong with NantWorks led the October 6, 2026 financing. New investors AstraZeneca, Lingotto, Teradyne, and Strange Ventures joined returning backers Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund, bringing Multiply Labs' disclosed capital since 2016 to more than $100M.

The San Francisco company builds robotic clusters that automate biologics manufacturing with equipment pharmaceutical companies already use. The capital is meant to expand manufacturing capacity, accelerate the product roadmap, and grow engineering, regulatory, and commercial teams as Multiply Labs moves from clinical-stage deployments toward commercial-scale production.

What Multiply Labs Announced

The $75M Series B follows a $20M Series A announced in April 2021 and led by Casdin Capital. Multiply Labs said the new round lifts total capital raised to more than $100M, but it did not disclose a valuation, revenue, or the number of live customer installations.

The investor group crosses medicine, industrial technology, and venture capital. AstraZeneca is both a new investor and a previously announced collaborator. Teradyne brings an industrial-automation lens, while NantWorks founder Patrick Soon-Shiong has spent decades building and financing companies across biotechnology, medicine, and data.

Ileana Pirozzi of Lingotto Innovation is joining the board. The company said it will use the financing to increase manufacturing capacity, speed product development, and add people across functions that become unavoidable when a machine moves from a controlled deployment into a regulated production environment.

Why Manufacturing Has Become the Bottleneck

AI can propose more drug candidates and make discovery cycles faster, but every approved therapy still has to be produced in the physical world. Advanced biologics are especially demanding because their manufacturing depends on sterile environments, tightly controlled steps, reliable records, and, in some cases, patient-specific material that cannot be treated like a large batch of identical pills.

Multiply Labs began with individualized medicines and later concentrated on cell and gene therapy. Its current roadmap extends to antibodies, viral vectors, and mRNA, widening the range of processes the platform must support without weakening the controls that pharmaceutical customers already validated.

That is the commercial opening behind the round. Discovery software can scale by serving another user, but biologics capacity grows through instruments, clean-room space, trained labor, materials, quality systems, and repeatable physical work. Multiply Labs is trying to package more of that capacity as deployable robotic infrastructure.

How the Multiply Labs Robotic Cluster Works

The company connects existing GMP instruments inside an enclosed robotic cluster rather than asking a manufacturer to replace an entire process. Robotic arms and customized modules handle transfers and repetitive unit operations, while the software coordinates instruments, captures sensor data, and sends electronic records into a customer's quality workflow.

Multiply Labs describes its system as autonomous rather than merely automated. Its imitation-learning approach uses demonstrations from scientists to train robots on existing workflows, allowing the machinery to adapt to a customer's process instead of forcing the customer through a wholesale process transfer.

The ownership model is equally important. Pharmaceutical and biologics companies own and operate the clusters rather than sending production to Multiply Labs as an outsourced service. That keeps capacity, manufacturing data, and supply-chain control inside the customer while making Multiply Labs responsible for equipment reliability, integration, software, service, and the economics of expanding each installation.

What the Evidence Supports

Multiply Labs says its clusters can reduce cost per dose by 74% and produce up to 100 times more patient doses per square foot than manual manufacturing. Those figures are useful indicators, but they should remain attributed to the company and the study context behind them rather than treated as audited performance across every commercial deployment.

A 2024 peer-reviewed Cytotherapy study documented a robotic cluster using standard cell-therapy instruments and compared automated work with manual processes. The paper supports the technical feasibility of the approach, while its conflict disclosures show that many authors were current or former Multiply Labs employees or equity holders and that academic collaborators received company support.

The company lists AstraZeneca, Legend Biotech, and Kyverna Therapeutics as announced collaborations. Those relationships show that large biopharma organizations are willing to test or deploy the model, but Multiply Labs has not publicly disclosed enough production, revenue, or customer data to measure broad commercial adoption.

The Founders Combined Pharma and Robotics

Co-founder and CEO Fred Parietti earned a PhD in mechanical engineering and robotics at MIT. Co-founder and CSO Alice Melocchi worked in pharmaceutical research at the University of Milan and the MIT-Novartis Center for Continuous Manufacturing.

MIT News reported that Melocchi saw a connection between drug formulation and Parietti's robotics work, while Parietti built an early prototype in his Cambridge apartment. After Y Combinator, the company shifted from personalized capsules toward pharmaceutical manufacturing and then into cell-therapy automation.

That origin still shapes the product. Multiply Labs is not selling a robot that happens to stand in a clean room. It is trying to combine robotics, pharmaceutical process knowledge, software control, and compliance records into one manufacturing system.

What the $75M Changes

The Series B gives Multiply Labs more room to manufacture its own systems, train them on more workflows, and support customers moving toward commercial production. It also raises the standard of proof because a commercial-scale platform has to work through maintenance, validation, supply-chain changes, quality review, and the everyday exceptions that never appear in a polished demonstration.

The strongest part of the strategy is continuity. Customers can keep familiar instruments and retain control of production while adding automation around the work. The hardest part is that every additional therapy class, customer process, and facility creates another set of details the system must understand without compromising repeatability.

Multiply Labs has spent years proving that robots can execute sensitive laboratory operations. With $75M behind the next phase, the company now has to make those robots dependable coworkers inside factories where a missed handoff can become a lost batch, a delayed therapy, and a patient still waiting.